The instructive extracellular matrix of the lung: Basic composition and alterations in chronic lung disease

European Respiratory Journal

Volumn 50, Issue 1, 2017, Pages

  Burgstaller, Gerald ^a   Oehrle, Bettina ^a   Gerckens, Michael ^a   White, Eric S ^b   Schiller, Herbert B ^a   Eickelberg, Oliver ^c  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOMATERIAL; COLLAGEN TYPE 1; COLLAGEN TYPE 4; FIBRONECTIN; GLYCOSAMINOGLYCAN; LAMININ; MATRIX PROTEIN; TENASCIN; SCLEROPROTEIN;

ASTHMA; CELL DIFFERENTIATION; CELL FUNCTION; CHRONIC LUNG DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; EXTRACELLULAR MATRIX; FIBROSING ALVEOLITIS; HUMAN; LUNG CANCER; LUNG DEVELOPMENT; LUNG FUNCTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MODIFICATION; PROTEIN SECRETION; PULMONARY HYPERTENSION; REVIEW; SMALL CELL LUNG CANCER; SOLID; ADULT; AIRWAY REMODELING; CHRONIC DISEASE; LUNG; LUNG DISEASE; METABOLISM; PATHOPHYSIOLOGY; PROTEOMICS;

ADULT; AIRWAY REMODELING; CHRONIC DISEASE; EXTRACELLULAR MATRIX; EXTRACELLULAR MATRIX PROTEINS; HUMANS; LUNG; LUNG DISEASES; PROTEOMICS;

EID: 85026262754     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.01805-2016     Document Type: Review

References (181)

1. Hynes RO. The extracellular matrix: not just pretty fibrils. Science 2009; 326: 1216-1219.
2. Sorokin L. The impact of the extracellular matrix on inflammation. Nat Rev Immunol 2010; 10: 712-723.
3. Naba A, Hoersch S, Hynes RO. Towards definition of an ECM parts list: An advance on GO categories. Matrix Biol 2012; 31: 371-372.
4. Hynes RO, Naba A. Overview of the matrisome-an inventory of extracellular matrix constituents and functions. Cold Spring Harb Perspect Biol 2012; 4: A004903.
5. Naba A, Clauser KR, Hoersch S, et al. The matrisome: In silico definition and in vivo characterization by proteomics of normal and tumor extracellular matrices. Mol Cell Proteomics 2012; 11: M111.014647.
6. Naba A, Clauser KR, Lamar JM, et al. Extracellular matrix signatures of human mammary carcinoma identify novel metastasis promoters. Elife 2014; 3: E01308.
7. Naba A, Clauser KR, Hoersch S, et al. The matrisome: In silico definition and in vivo characterization by proteomics of normal and tumor extracellular matrices. Mol Cell Proteomics 2012; 11: M111 014647.
8. Rashid ST, Humphries JD, Byron A, et al. Proteomic analysis of extracellular matrix from the hepatic stellate cell line LX-2 identifies CYR61 and Wnt-5a as novel constituents of fibrotic liver. J Proteome Res 2012; 11: 4052-4064.
9. Zanivan S, Maione F, Hein MY, et al. SILAC-based proteomics of human primary endothelial cell morphogenesis unveils tumor angiogenic markers. Mol Cell Proteomics 2013; 12: 3599-3611.
10. Didangelos A, Yin X, Mandal K, et al. Proteomics characterization of extracellular space components in the human aorta. Mol Cell Proteomics 2010; 9: 2048-2062.
11. Barallobre-Barreiro J, Didangelos A, Schoendube FA, et al. Proteomics analysis of cardiac extracellular matrix remodeling in a porcine model of ischemia/reperfusion injury. Circulation 2012; 125: 789-802.
12. Schiller HB, Fernandez IE, Burgstaller G, et al. Time- and compartment-resolved proteome profiling of the extracellular niche in lung injury and repair. Mol Syst Biol 2015; 11: 819.
13. Booth AJ, Hadley R, Cornett AM, et al. Acellular normal and fibrotic human lung matrices as a culture system for in vitro investigation. Am J Respir Crit Care Med 2012; 186: 866-876.
14. Wisniewski JR, Hein MY, Cox J, et al. A "proteomic ruler" for protein copy number and concentration estimation without spike-in standards. Mol Cell Proteomics, 2014; 13: 3497-3506.
15. Suki B, Ito S, Stamenovic D, et al. Biomechanics of the lung parenchyma: Critical roles of collagen and mechanical forces. J Appl Physiol (1985) 2005; 98: 1892-1899.
16. Suki B, Bates JH. Extracellular matrix mechanics in lung parenchymal diseases. Respir Physiol Neurobiol 2008; 163: 33-43.
17. Faffe DS, Zin WA. Lung parenchymal mechanics in health and disease. Physiol Rev 2009; 89: 759-775.
18. Wagenseil JE, Mecham RP. New insights into elastic fiber assembly. Birth Defects Res C Embryo Today 2007; 81: 229-240.
19. Sakai LY, Keene DR, Glanville RW, et al. Purification and partial characterization of fibrillin, a cysteine-rich structural component of connective tissue microfibrils. J Biol Chem 1991; 266: 14763-14770.
20. Wulf-Johansson H, Lock Johansson S, Schlosser A, et al. Localization of microfibrillar-associated protein 4 (MFAP4) in human tissues: Clinical evaluation of serum MFAP4 and its association with various cardiovascular conditions. PLoS One 2013; 8: E82243.
21. Molleken C, Poschmann G, Bonella F, et al. MFAP4: A candidate biomarker for hepatic and pulmonary fibrosis?. Sarcoidosis Vasc Diffuse Lung Dis 2016; 33: 41-50.
22. Frantz C, Stewart KM, Weaver VM. The extracellular matrix at a glance. J Cell Sci, 2010; 123(Pt 24): 4195-4200.
23. Bosman FT, Stamenkovic I. Functional structure and composition of the extracellular matrix. J Pathol 2003; 200: 423-428.
24. Humphrey JD, Dufresne ER, Schwartz MA. Mechanotransduction and extracellular matrix homeostasis. Nat Rev Mol Cell Biol 2014; 15: 802-812.
25. Nakamura T, Lozano PR, Ikeda Y, et al. Fibulin-5/DANCE is essential for elastogenesis in vivo. Nature 2002; 415: 171-175.
26. Spessotto P, Cervi M, Mucignat MT, et al. beta 1 Integrin-dependent cell adhesion to EMILIN-1 is mediated by the gC1q domain. J Biol Chem 2003; 278: 6160-6167.
27. Ruoslahti E, Pierschbacher MD. New perspectives in cell adhesion: RGD and integrins. Science 1987; 238: 491-497.
28. Dunsmore SE, Rannels DE. Extracellular matrix biology in the lung. Am J Physiol, 1996; 270: L3-L27.
29. Iozzo RV. Matrix proteoglycans: From molecular design to cellular function. Annu Rev Biochem 1998; 67: 609-652.
30. Kolb M, Margetts PJ, Sime PJ, et al. Proteoglycans decorin and biglycan differentially modulate TGF-beta-mediated fibrotic responses in the lung. Am J Physiol Lung Cell Mol Physiol 2001; 280: L1327-L1334.
31. Theocharis AD, Gialeli C, Bouris P, et al. Cell-matrix interactions: Focus on proteoglycan-proteinase interplay and pharmacological targeting in cancer. FEBS J 2014; 281: 5023-5042.
32. Erler JT, Weaver VM. Three-dimensional context regulation of metastasis. Clin Exp Metastasis 2009; 26: 35-49.
33. Cox TR, Bird D, Baker AM, et al. LOX-mediated collagen crosslinking is responsible for fibrosis-enhanced metastasis. Cancer Res 2013; 73: 1721-1732.
34. Xiao Q, Ge G. Lysyl oxidase, extracellular matrix remodeling and cancer metastasis. Cancer Microenviron 2012; 5: 261-273.
35. Iismaa SE, Mearns BM, Lorand L, et al. Transglutaminases and disease: Lessons from genetically engineered mouse models and inherited disorders. Physiol Rev 2009; 89: 991-1023.
36. Li Y, Fessel G, Georgiadis M, et al. Advanced glycation end-products diminish tendon collagen fiber sliding. Matrix Biol 2013; 32: 169-177.
37. Jaisson S, Lorimier S, Ricard-Blum S, et al. Impact of carbamylation on type I collagen conformational structure and its ability to activate human polymorphonuclear neutrophils. Chem Biol 2006; 13: 149-159.
38. Watson WH, Ritzenthaler JD, Roman J. Lung extracellular matrix and redox regulation. Redox Biol 2016; 8: 305-315.
39. Daniil ZD, Papageorgiou E, Koutsokera A, et al. Serum levels of oxidative stress as a marker of disease severity in idiopathic pulmonary fibrosis. Pulm Pharmacol Ther 2008; 21: 26-31.
40. Montuschi P, Corradi M, Ciabattoni G, et al. Increased 8-isoprostane, a marker of oxidative stress, in exhaled condensate of asthma patients. Am J Respir Crit Care Med 1999; 160: 216-220.
41. Shelef MA, Bennin DA, Mosher DF, et al. Citrullination of fibronectin modulates synovial fibroblast behavior. Arthritis Res Ther 2012; 14: R240.
42. Seet BT, Dikic I, Zhou MM, et al. Reading protein modifications with interaction domains. Nat Rev Mol Cell Biol 2006; 7: 473-483.
43. Kristensen JH, Karsdal MA, Genovese F, et al. The role of extracellular matrix quality in pulmonary fibrosis. Respiration 2014; 88: 487-499.
44. Walsh G, Jefferis R. Post-translational modifications in the context of therapeutic proteins. Nat Biotechnol 2006; 24: 1241-1252.
45. Leeming DJ, Bay-Jensen AC, Vassiliadis E, et al. Post-translational modifications of the extracellular matrix are key events in cancer progression: Opportunities for biochemical marker development. Biomarkers 2011; 16: 193-205.
46. Hynes RO. Integrins: Bidirectional, allosteric signaling machines. Cell 2002; 110: 673-687.
47. Schiller HB, Fassler R. Mechanosensitivity and compositional dynamics of cell-matrix adhesions. EMBO Rep 2013; 14: 509-519.
48. Geiger B, Spatz JP, Bershadsky AD. Environmental sensing through focal adhesions. Nat Rev Mol Cell Biol 2009; 10: 21-33.
49. Zaidel-Bar R, Itzkovitz S, Ma'ayan A, et al. Functional atlas of the integrin adhesome. Nat Cell Biol 2007; 9: 858-867.
50. Schiller HB, Hermann MR, Polleux J, et al. β1- and αv-class integrins cooperate to regulate myosin II during rigidity sensing of fibronectin-based microenvironments. Nat Cell Biol 2013; 15: 625-636.
51. Schiller HB, et al. Quantitative proteomics of the integrin adhesome show a myosin II-dependent recruitment of LIM domain proteins. EMBO Rep 2011; 12: 259-266.
52. Kuo JC, Han X, Hsiao CT, et al. Analysis of the myosin-II-responsive focal adhesion proteome reveals a role for beta-Pix in negative regulation of focal adhesion maturation. Nat Cell Biol 2011; 13: 383-393.
53. Horton ER, Byron A, Askari JA, et al. Definition of a consensus integrin adhesome and its dynamics during adhesion complex assembly and disassembly. Nat Cell Biol 2015; 17: 1577-1587.
54. Geiger T, Zaidel-Bar R. Opening the floodgates: Proteomics and the integrin adhesome. Curr Opin Cell Biol 2012; 24: 562-568.
55. Humphries JD, Byron A, Bass MD, et al. Proteomic analysis of integrin-associated complexes identifies RCC2 as a dual regulator of Rac1 and Arf6. Sci Signal 2009; 2: Ra51.
56. Connelly JT, Gautrot JE, Trappmann B, et al. Actin and serum response factor transduce physical cues from the microenvironment to regulate epidermal stem cell fate decisions. Nature Cell Biol 2010; 12: 711-718.
57. Zhou Y, Huang X, Hecker L, et al. Inhibition of mechanosensitive signaling in myofibroblasts ameliorates experimental pulmonary fibrosis. J Clin Invest 2013; 123: 1096-1108.
58. Lu P, Weaver VM, Werb Z. The extracellular matrix: A dynamic niche in cancer progression. J Cell Biol 2012; 196: 395-406.
59. Levental KR, Yu H, Kass L, et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 2009; 139: 891-906.
60. Huang X, Gai Y, Yang N, et al. Relaxin regulates myofibroblast contractility and protects against lung fibrosis. Am J Pathol 2011; 179: 2751-2765.
61. Kai F, Laklai H, Weaver VM. Force matters: Biomechanical regulation of cell invasion and migration in disease. Trends Cell Biol 2016; 26: 486-497.
62. Engler A, Bacakova L, Newman C, et al. Substrate compliance versus ligand density in cell on gel responses. Biophys J, 2004; 86: 617-628.
63. Lo CM, et al. Cell movement is guided by the rigidity of the substrate. Biophys J 2000; 79: 144-152.
64. Vincent LG, Choi YS, Alonso-Latorre B, et al. Mesenchymal stem cell durotaxis depends on substrate stiffness gradient strength. Biotechnol J 2013; 8: 472-484.
65. Lee S, Hong J, Lee J. Cell motility regulation on a stepped micro pillar array device (SMPAD) with a discrete stiffness gradient. Soft Matter 2016; 12: 2325-2333.
66. Fu J, Wang YK, Yang MT, et al. Mechanical regulation of cell function with geometrically modulated elastomeric substrates. Nat Methods 2010; 7: 733-736.
67. Goffin JM, Pittet P, Csucs G, et al. Focal adhesion size controls tension-dependent recruitment of alpha-smooth muscle actin to stress fibers. J Cell Biol 2006; 172: 259-268.
68. Liu F, Mih JD, Shea BS, et al. Feedback amplification of fibrosis through matrix stiffening and COX-2 suppression. J Cell Biol 2010; 190: 693-706.
69. Arnaout MA, Goodman SL, Xiong JP. Structure and mechanics of integrin-based cell adhesion. Curr Opin Cell Biol 2007; 19: 495-507.
70. Patel NR, Bole M, Chen C, et al. Cell elasticity determines macrophage function. PLoS One 2012; 7: E41024.
71. Krishnan R, Klumpers DD, Park CY, et al. Substrate stiffening promotes endothelial monolayer disruption through enhanced physical forces. Am J Physiol Cell Physiol 2011; 300: C146-C154.
72. Taipale J, Keski-Oja J. Growth factors in the extracellular matrix. Faseb J 1997; 11: 51-59.
73. Bonnans C, Chou J, Werb Z. Remodelling the extracellular matrix in development and disease. Nat Rev Mol Cell Biol 2014; 15: 786-801.
74. Overall CM. Molecular determinants of metalloproteinase substrate specificity: Matrix metalloproteinase substrate binding domains, modules, and exosites. Mol Biotechnol 2002; 22: 51-86.
75. Sand JM, Larsen L, Hogaboam C, et al. MMP mediated degradation of type IV collagen alpha 1 and alpha 3 chains reflects basement membrane remodeling in experimental and clinical fibrosis-validation of two novel biomarker assays. PLoS One 2013; 8: E84934.
76. Willenbrock F, Crabbe T, Slocombe PM, et al. The activity of the tissue inhibitors of metalloproteinases is regulated by C-terminal domain interactions: A kinetic analysis of the inhibition of gelatinase A. Biochemistry 1993; 32: 4330-4337.
77. van Goor H, Melenhorst WBWH, Turner AJ, et al. Adamalysins in biology and disease. J Pathol 2009; 219: 277-286.
78. Byrne AJ, Mathie SA, Gregory LG, et al. Pulmonary macrophages: Key players in the innate defence of the airways. Thorax 2015; 70: 1189-1196.
79. Pardo A, Cabrera S, Maldonado M, et al. Role of matrix metalloproteinases in the pathogenesis of idiopathic pulmonary fibrosis. Respir Res 2016; 17: 23.
80. Zuo F, Kaminski N, Eugui E, et al. Gene expression analysis reveals matrilysin as a key regulator of pulmonary fibrosis in mice and humans. Proc Natl Acad Sci USA 2002; 99: 6292-6297.
81. Lu P, Takai K, Weaver VM, et al. Extracellular matrix degradation and remodeling in development and disease. Cold Spring Harb Perspect Biol 2011; 3(12).
82. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2071-2082.
83. King TE Jr, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2083-2092.
84. Noble PW, Barkauskas CE, Jiang D. Pulmonary fibrosis: Patterns and perpetrators. J Clin Invest 2012; 122: 2756-2762.
85. Wolters PJ, Collard HR, Jones KD. Pathogenesis of idiopathic pulmonary fibrosis. Annu Rev Pathol 2014; 9: 157-179.
86. Fernandez IE, Eickelberg O. New cellular and molecular mechanisms of lung injury and fibrosis in idiopathic pulmonary fibrosis. Lancet 2012; 380: 680-688.
87. Hashimoto N, Jin H, Liu T, et al. Bone marrow-derived progenitor cells in pulmonary fibrosis. J Clin Invest 2004; 113: 243-252.
88. Quan TE, Cowper S, Wu SP, et al. Circulating fibrocytes: Collagen-secreting cells of the peripheral blood. Int J Biochem Cell Biol 2004; 36: 598-606.
89. Bellini A, Mattoli S. The role of the fibrocyte, a bone marrow-derived mesenchymal progenitor, in reactive and reparative fibroses. Lab Invest 2007; 87: 858-870.
90. Willis BC, Liebler JM, Luby-Phelps K, et al. Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-beta1: Potential role in idiopathic pulmonary fibrosis. Am J Pathol 2005; 166: 1321-1332.
91. Tsukui T, Ueha S, Shichino S, et al. Intratracheal cell transfer demonstrates the profibrotic potential of resident fibroblasts in pulmonary fibrosis. Am J Pathol 2015; 185: 2939-2948.
92. Hung C, Linn G, Chow YH, et al. Role of lung pericytes and resident fibroblasts in the pathogenesis of pulmonary fibrosis. Am J Respir Crit Care Med 2013; 188: 820-830.
93. Rock JR, Barkauskas CE, Cronce MJ, et al. Multiple stromal populations contribute to pulmonary fibrosis without evidence for epithelial to mesenchymal transition. Proc Natl Acad Sci USA 2011; 108: E1475-E1483.
94. Parker MW, Rossi D, Peterson M, et al. Fibrotic extracellular matrix activates a profibrotic positive feedback loop. J Clin Invest 2014; 124:1622-1635.
95. Ott HC, Clippinger B, Conrad C, et al. Regeneration and orthotopic transplantation of a bioartificial lung. Nat Med 2010; 16: 927-933.
96. Song JJ, Kim SS, Liu Z, et al. Enhanced in vivo function of bioartificial lungs in rats. Ann Thorac Surg 2011; 92: 998-1005.
97. Wagner DE, Bonvillain RW, Jensen T, et al. Can stem cells be used to generate new lungs?. Ex vivo lung bioengineering with decellularized whole lung scaffolds. Respirology 2013; 18: 895-911.
98. Wagner DE, Bonenfant NR, Parsons CS, et al. Comparative decellularization and recellularization of normal versus emphysematous human lungs. Biomaterials 2014; 35: 3281-3297.
99. Malanchi I, Santamaria-Martínez A, Susanto E, et al. Interactions between cancer stem cells and their niche govern metastatic colonization. Nature 2012; 481: 85-89.
100. Baghy K, Iozzo RV, Kovalszky I. Decorin-TGFβ axis in hepatic fibrosis and cirrhosis. J Histochem Cytochem 2012; 60: 262-268.
101. Marastoni S, Andreuzzi E, Paulitti A, et al. EMILIN2 down-modulates the Wnt signalling pathway and suppresses breast cancer cell growth and migration. J Pathol 2014; 232: 391-404.
102. Calderwood CJ, Jones MG, Hoile L, et al. Secreted lysyl oxidase is elevated in the bronchoalveolar lavage fluid of patients with idiopathic pulmonary fibrosis. Thorax 2012; 67: A111.
103. Olsen KC, Sapinoro RE, Kottmann RM, et al. Transglutaminase 2 and its role in pulmonary fibrosis. Am J Respir Crit Care Med 2011; 184: 699-707.
104. Henderson NC, Arnold TD, Katamura Y, et al. Targeting of αv integrin identifies a core molecular pathway that regulates fibrosis in several organs. Nat Med 2013; 19: 1617-1624.
105. Jenkins RG, Su X, Su G, et al. Ligation of protease-activated receptor 1 enhances alphavbeta6 integrin-dependent TGF-β activation and promotes acute lung injury. J Clin Invest 2006; 116: 1606-1614.
106. Decaris ML, Gatmaitan M, FlorCruz S, et al. Proteomic analysis of altered extracellular matrix turnover in bleomycin-induced pulmonary fibrosis. Mol Cell Proteomics 2014; 13: 1741-1752.
107. Gooptu B, Ekeowa UI, Lomas DA. Mechanisms of emphysema in α1-antitrypsin deficiency: Molecular and cellular insights. Eur Respir J 2009; 34: 475-488.
108. Snider GL, Lucey EC, Stone PJ. Animal models of emphysema. Am Rev Respir Dis 1986; 133: 149-169.
109. Suki B, Sato S, Parameswaran H, et al. Emphysema and mechanical stress-induced lung remodeling. Physiology (Bethesda) 2013; 28: 404-413.
110. Ito S, Ingenito EP, Brewer KK, et al. Mechanics, nonlinearity, and failure strength of lung tissue in a mouse model of emphysema: Possible role of collagen remodeling. J Appl Physiol (1985) 2005; 98: 503-511.
111. Finlay GA, O'Donnell MD, O'Connor CM, et al. Elastin and collagen remodeling in emphysema. A scanning electron microscopy study. Am J Pathol 1996; 149: 1405-1415.
112. Pacini A, Gardi C, Corradeschi F, et al. In vivo stimulation of lung collagen synthesis by collagen derived peptides. Res Commun Chem Pathol Pharmacol 1990; 68: 89-101.
113. Vlahovic G, Russell ML, Mercer RR, et al. Cellular and connective tissue changes in alveolar septal walls in emphysema. Am J Respir Crit Care Med 1999; 160: 2086-2092.
114. Annoni R, Lanças T, Yukimatsu Tanigawa R, et al. Extracellular matrix composition in COPD. Eur Respir J 2012; 40: 1362-1373.
115. Roman J, Ritzenthaler JD, Gil-Acosta A, et al. Nicotine and fibronectin expression in lung fibroblasts: Implications for tobacco-related lung tissue remodeling. FASEB J 2004; 18: 1436-1438.
116. Chen L, Ge Q, Tjin G, et al. Effects of cigarette smoke extract on human airway smooth muscle cells in COPD. Eur Respir J 2014; 44: 634-646.
117. Ramnath NW, van de Luijtgaarden KM, van der Pluijm I, et al. Extracellular matrix defects in aneurysmal Fibulin-4 mice predispose to lung emphysema. PLoS One 2014; 9: E106054.
118. Papaporfyriou A, Loukides S, Kostikas K, et al. Increased levels of osteopontin in sputum supernatant in patients with COPD. Chest 2014; 146: 951-958.
119. Pardo A, Gibson K, Cisneros J, et al. Up-regulation and profibrotic role of osteopontin in human idiopathic pulmonary fibrosis. PLoS Med 2005; 2: E251.
120. Hoonhorst SJ, Lo Tam Loi AT, Hartman JE, et al. Advanced glycation end products in the skin are enhanced in COPD. Metabolism 2014; 63: 1149-1156.
121. Sand JM, Knox AJ, Lange P, et al. Accelerated extracellular matrix turnover during exacerbations of COPD. Respir Res 2015; 16: 69.
122. Jonigk D, Golpon H, Bockmeyer CL, et al. Plexiform lesions in pulmonary arterial hypertension composition, architecture, and microenvironment. Am J Pathol 2011; 179: 167-179.
123. Stenmark KR, Meyrick B, Galie N, et al. Animal models of pulmonary arterial hypertension: The hope for etiological discovery and pharmacological cure. Am J Physiol Lung Cell Mol Physiol 2009; 297: L1013-L1032.
124. Poiani GJ, Tozzi CA, Yohn SE, et al. Collagen and elastin metabolism in hypertensive pulmonary arteries of rats. Circ Res 1990; 66: 968-978.
125. Jones PL, Cowan KN, Rabinovitch M. Tenascin-C, proliferation and subendothelial fibronectin in progressive pulmonary vascular disease. Am J Pathol 1997; 150: 1349-1360.
126. Karnik SK, Brooke BS, Bayes-Genis A, et al. A critical role for elastin signaling in vascular morphogenesis and disease. Development 2003; 130: 411-423.
127. Papakonstantinou E, Kouri FM, Karakiulakis G, et al. Increased hyaluronic acid content in idiopathic pulmonary arterial hypertension. Eur Respir J 2008; 32: 1504-1512.
128. Kalay N, Elcik D, Canatan H, et al. Elevated plasma hyaluronan levels in pulmonary hypertension. Tohoku J Exp Med 2013; 230: 7-11.
129. Lauer ME, Aytekin M, Comhair SA, et al. Modification of hyaluronan by heavy chains of inter-alpha-inhibitor in idiopathic pulmonary arterial hypertension. J Biol Chem 2014; 289: 6791-6798.
130. Lepetit H, Eddahibi S, Fadel E, et al. Smooth muscle cell matrix metalloproteinases in idiopathic pulmonary arterial hypertension. Eur Respir J 2005; 25: 834-842.
131. Coen M, Gabbiani G, Bochaton-Piallat ML. Myofibroblast-mediated adventitial remodeling: An underestimated player in arterial pathology. Arterioscler Thromb Vasc Biol 2011; 31: 2391-2396.
132. Nave AH, Mižíková I, Niess G, et al. Lysyl oxidases play a causal role in vascular remodeling in clinical and experimental pulmonary arterial hypertension. Arterioscler Thromb Vasc Biol 2014; 34: 1446-1458.
133. Scarritt ME, Bonvillain RW, Burkett BJ, et al. Hypertensive rat lungs retain hallmarks of vascular disease upon decellularization but support the growth of mesenchymal stem cells. Tissue Eng Part A 2014; 20: 1426-1443.
134. Mauad T, Silva LF, Santos MA, et al. Abnormal alveolar attachments with decreased elastic fiber content in distal lung in fatal asthma. Am J Respir Crit Care Med 2004; 170: 857-862.
135. Roche WR, Beasley R, Williams JH, et al. Subepithelial fibrosis in the bronchi of asthmatics. Lancet 1989; 1: 520-524.
136. Araujo BB, Dolhnikoff M, Silva LF, et al. Extracellular matrix components and regulators in the airway smooth muscle in asthma. Eur Respir J 2008; 32: 61-69.
137. Weitoft M, Andersson C, Andersson-Sjöland A, et al. Controlled and uncontrolled asthma display distinct alveolar tissue matrix compositions. Respir Res 2014; 15: 67.
138. Nihlberg K, Andersson-Sjöland A, Tufvesson E, et al. Altered matrix production in the distal airways of individuals with asthma. Thorax 2010; 65: 670-676.
139. Dekkers BG, Schaafsma D, Nelemans A, et al. Extracellular matrix proteins differentially regulate airway smooth muscle phenotype and function. Am J Physiol Lung Cell Mol Physiol 2007; 292: L1405-L1413.
140. Johnson PR, Burgess JK, Underwood PA, et al. Extracellular matrix proteins modulate asthmatic airway smooth muscle cell proliferation via an autocrine mechanism. J Allergy Clin Immunol 2004; 113: 690-696.
141. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011; 144: 646-674.
142. Pickup MW, Mouw JK, Weaver VM. The extracellular matrix modulates the hallmarks of cancer. EMBO Rep 2014; 15: 1243-1253.
143. Sethi T, Rintoul RC, Moore SM, et al. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: A mechanism for small cell lung cancer growth and drug resistance in vivo. Nat Med 1999; 5: 662-668.
144. Sivridis E, Giatromanolaki A, Koukourakis MI. "Stromatogenesis" and tumor progression. Int J Surg Pathol 2004; 12: 1-9.
145. Chen Y, Terajima M, Yang Y, et al. Lysyl hydroxylase 2 induces a collagen cross-link switch in tumor stroma. J Clin Invest 2015; 125: 1147-1162.
146. Barker HE, Cox TR, Erler JT. The rationale for targeting the LOX family in cancer. Nat Rev Cancer 2012; 12: 540-552.
147. Mouw JK, Yui Y, Damiano L, et al. Tissue mechanics modulate microRNA-dependent PTEN expression to regulate malignant progression. 2014; 20: 360-367.
148. Paszek MJ, Zahir N, Johnson KR, et al. Tensional homeostasis and the malignant phenotype. Cancer Cell 2005; 8: 241-254.
149. Whipple CA. Tumor talk: Understanding the conversation between the tumor and its microenvironment. Cancer Cell Microenviron 2015; 2: E773.
150. Vancheri C. Idiopathic pulmonary fibrosis and cancer: Do they really look similar?. BMC Med 2015; 13: 220.
151. Vancheri C, Failla M, Crimi N, et al. Idiopathic pulmonary fibrosis: A disease with similarities and links to cancer biology. Eur Respir J 2010; 35: 496-504.
152. Vancheri C. Idiopathic pulmonary fibrosis: An altered fibroblast proliferation linked to cancer biology. Proc Am Thorac Soc 2012; 9: 153-157.
153. Antoniou KM, Tomassetti S, Tsitoura E, et al. Idiopathic pulmonary fibrosis and lung cancer: A clinical and pathogenesis update. Curr Opin Pulm Med 2015; 21: 626-633.
154. Vancheri C. Common pathways in idiopathic pulmonary fibrosis and cancer. Eur Respir Rev 2013; 22: 265-272.
155. Burgstaller G, Oehrle B, Koch I, et al. Multiplex profiling of cellular invasion in 3D cell culture models. PLoS One 2013; 8: E63121.
156. Marques-Garcia F, Marcos-Vadillo E. Review of mouse models applied to the study of asthma. Methods Mol Biol 2016; 1434: 213-222.
157. Nogueira-Ferreira R, Vitorino R, Ferreira R, et al. Exploring the monocrotaline animal model for the study of pulmonary arterial hypertension: A network approach. Pulm Pharmacol Ther 2015; 35: 8-16.
158. Ryan JJ, Marsboom G, Archer SL. Rodent models of group 1 pulmonary hypertension. Handb Exp Pharmacol 2013; 218: 105-149.
159. Gazdar AF, Hirsch FR, Minna JD. From mice to men and back: An assessment of preclinical model systems for the study of lung cancers. J Thorac Oncol 2016; 11: 287-299.
160. Fricker M, Deane A, Hansbro PM. Animal models of chronic obstructive pulmonary disease. Expert Opin Drug Discov 2014; 9: 629-645.
161. Mizikova I, Morty RE. The extracellular matrix in bronchopulmonary dysplasia: Target and source. Front Med (Lausanne) 2015; 2: 91.
162. Moore B, Lawson WE, Oury TD, et al. Animal models of fibrotic lung disease. Am J Respir Cell Mol Biol 2013; 49: 167-179.
163. Cukierman E, Pankov R, Yamada KM. Cell interactions with three-dimensional matrices. Curr Opin Cell Biol 2002; 14: 633-639.
164. Baker BM, Chen CS. Deconstructing the third dimension: How 3D culture microenvironments alter cellular cues. J Cell Sci, 2012; 125: 3015-3024.
165. Abbott A. Cell culture: Biology's new dimension. Nature 2003; 424: 870-872.
166. Thannickal VJ, Henke CA, Horowitz JC, et al. Matrix biology of idiopathic pulmonary fibrosis: A workshop of the National Heart, Lung, and Blood Institute. Am J Pathol 2014; 184: 1643-1651.
167. Hinz B. Mechanical aspects of lung fibrosis: A spotlight on the myofibroblast. Proc Am Thorac Soc 2012; 9: 137-147.
168. White ES. Lung extracellular matrix and fibroblast function. Ann Am Thorac Soc, 2015; 12 Suppl. 1: S30-S33.
169. Saums MK, Wang W, Han B, et al. Mechanically and chemically tunable cell culture system for studying the myofibroblast phenotype. Langmuir 2014; 30: 5481-5487.
170. Silver FH, Pins G. Cell growth on collagen: A review of tissue engineering using scaffolds containing extracellular matrix. J Long Term Eff Med Implants 1992; 2: 67-80.
171. Hafemann B, Ensslen S, Erdmann C, et al. Use of a collagen/elastin-membrane for the tissue engineering of dermis. Burns 1999; 25: 373-384.
172. Hayen W, Goebeler M, Kumar S, et al. Hyaluronan stimulates tumor cell migration by modulating the fibrin fiber architecture. J Cell Sci 1999; 112: 2241-2251.
173. Rodin S, Antonsson L, Niaudet C, et al. Clonal culturing of human embryonic stem cells on laminin-521/E-cadherin matrix in defined and xeno-free environment. Nat Commun 2014; 5: 3195.
174. Raeber GP, Lutolf MP, Hubbell JA. Molecularly engineered PEG hydrogels: A novel model system for proteolytically mediated cell migration. Biophys J 2005; 89: 1374-1388.
175. Goetz JG, Minguet S, Navarro-Lérida I, et al. Biomechanical remodeling of the microenvironment by stromal caveolin-1 favors tumor invasion and metastasis. Cell 2011; 146: 148-163.
176. Uhl FE, Vierkotten S, Wagner DE, et al. Preclinical validation and imaging of Wnt-induced repair in human 3D lung tissue cultures. Eur Respir J 2015; 46: 1150-1166.
177. Burgstaller G, Vierkotten S, Lindner M, et al. Multidimensional immunolabeling and 4D time-lapse imaging of vital ex vivo lung tissue. Am J Physiol Lung Cell Mol Physiol 2015; 309: L323-L332.
178. Donovan C, Bailey SR, Tran J, et al. Rosiglitazone elicits in vitro relaxation in airways and precision cut lung slices from a mouse model of chronic allergic airways disease. Am J Physiol Lung Cell Mol Physiol 2015; 309: L1219-L1228.
179. Goldstein TA, Smith BD, Zeltsman D, et al. Introducing a 3-dimensionally printed, tissue-engineered graft for airway reconstruction: A pilot study. Otolaryngol Head Neck Surg 2015; 15: 1001-1006.
180. Psaila B, Lyden D. The metastatic niche: Adapting the foreign soil. Nat Rev Cancer 2009; 9: 285-293.
181. Burgess JK, Mauad T, Tjin G, et al. The extracellular matrix - the under-recognized element in lung disease?. J Pathol 2016; 240: 397-409.